Want to see GANX full AI Analyst Report?
GANX Stock Chart & Stats
$1.90
-$0.07(-3.85%)
At close: 4:00 PM EDT
$1.90
-$0.07(-3.85%)
Day’s Range― - ―
52-Week Range$1.53 - $4.34
Previous Close$1.75
Volume471.96K
Average Volume (3M)457.66K
Market Cap
$78.56M
Enterprise Value$74.57
Total Cash (Recent Filing)$13.08M
Total Debt (Recent Filing)$609.87K
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Nov 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding43,643,620
10 Day Avg. Volume364,400
30 Day Avg. Volume457,661
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.20Price Target Upside278.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityLow debt and positive equity provide financial flexibility relative to many early-stage biotechs. This reduces immediate leverage risk and may help the company fund development without debt-service pressure, although continued losses could weaken this position.
Cash Runway Supports Clinical ExecutionFunding into Q2 2027 gives Gain Therapeutics time to complete the Phase 1b extension and initiate Phase 2 without an immediate capital raise. This supports clinical continuity and reduces near-term financing disruption to the development plan.
GT-02287 Advanced Into Phase 2FDA authorization and planned multinational Phase 2a testing represent meaningful pipeline progression. Advancing an oral candidate into a controlled efficacy stage can strengthen the program’s strategic value and provide a clearer path toward validating its Parkinson’s approach.
Bears Say
No Meaningful Revenue BaseThe absence of meaningful revenue confirms that the company remains dependent on external financing while its drug candidates are developed. Until a product is commercialized or partnered, operating performance will remain highly exposed to clinical and funding outcomes.
Sustained Operating Cash BurnPersistent negative operating and free cash flow means the business is not self-funding. Continued investment in trials will consume available resources, making future financing, partnering, or successful clinical progress important to preserve operations beyond the stated runway.
Persistent Losses Threaten Equity ValueLarge recurring losses and sharply negative returns on equity indicate ongoing value erosion despite low debt. If cash burn persists, accumulated deficits and potential future equity issuance could reduce financial flexibility and dilute existing ownership.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $1.53 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics’s market cap?
Gain Therapeutics’s market cap is $78.56M.
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 73 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.028.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 43,643,620 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went up 16.384%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (278.95% Upside)
$7.20 (278.95% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 176.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Gain Therapeutics
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.20
▲(278.95% Upside)
Technical Analysis
Ownership Overview
2.23%
Insiders
1.72% Mutual Funds
3.85% Other Institutional Investors
90.65% Public Companies and
Individual Investors